Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Novel RORg inverse agonists do not modulate androgen receptor activity in prostate cancer


ABSTRACT: Work published by Wang et al. described pharmacological inhibition of RORg with an inverse agonist (SR2211) which led to a decrease in AR gene expression and a reduction in AR protein, which led to the loss of an AR gene expression signature. We have developed a novel, specific, RORg inverse agonist (AZ RORgi) and have studied its effects on the transcriptome of LNCAP cell lines following 24 & 48 hours of treatment. We compare this to SR2211 as well as Enzalutamide, an AR antagonist. We show that Enzalutamide and SR2211 primarily act via the androgen receptor, whereas AZ RORgi does not modulate gene expression in these cell lines.

INSTRUMENT(S): Illumina HiSeq 4000

ORGANISM(S): Homo sapiens

SUBMITTER: James Lynch 

PROVIDER: E-MTAB-7294 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Similar Datasets

2016-06-10 | E-GEOD-69896 | biostudies-arrayexpress
2016-06-10 | GSE69896 | GEO
2023-06-25 | GSE205980 | GEO
2019-09-03 | GSE125014 | GEO
2013-12-27 | E-GEOD-51872 | biostudies-arrayexpress
2013-04-01 | E-GEOD-44905 | biostudies-arrayexpress
2013-12-27 | GSE51872 | GEO
2010-06-21 | GSE21069 | GEO
| PRJNA848752 | ENA
2024-01-01 | GSE245417 | GEO